| Date | Title | | | 12/14/12 | ARIAD Announces Accelerated Approval by FDA of Iclusig (Ponatinib) for Patients with CML and Ph+ ALL Resistant or Intolerant to Prior Tyrosine Kinase Inhibitor Therapy|
The Iclusig™ bottle (Photo: Business Wire)
~Approved for All Phases of CML
~Product Expected to be Available to Patients Within Approximately Two Weeks
~Conference Call Scheduled Today at 1:30 p.m. ET
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that following a priority review, the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Iclusig™ (ponatinib) for the treatment of adult patients with chronic, accelerated or blast phase chronic m... |
|  | | 12/11/12 | ARIAD Announces 12-Month Data from Pivotal PACE Trial of Ponatinib in Heavily Pretreated Patients with Advanced-Phase CML and Ph+ ALL|
57 percent major hematologic response and median response duration
of 12 months in accelerated-phase CML patients reported
Median overall survival not yet reached in accelerated-phase CML
patients
ATLANTA & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 11, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced twelve-month
follow-up data from the pivotal PACE trial of ponatinib,
its investigational BCR-ABL inhib... |
| | | 12/10/12 | ARIAD Announces Long-Term Molecular Response Data on Ponatinib|
51 percent of chronic-phase CML patients in Phase 1 trial and 34
percent in Phase 2 PACE trial achieve major molecular response
ATLANTA & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 10, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated
molecular response data from its Phase 1 and pivotal Phase 2 trials of
ponatinib, its investigational BCR-ABL inhibitor, in heavily pretreated
patients with resistant or i... |
| | | 12/09/12 | ARIAD Announces 12-Month Data from Pivotal PACE Trial of Ponatinib in Heavily Pretreated Chronic-Phase CML Patients|
56 percent major cytogenetic response and 34 percent major
molecular response reported
ATLANTA, & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 9, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced twelve-month
follow-up data from the pivotal PACE trial of ponatinib,
its investigational BCR-ABL inhibitor, in heavily pretreated patients
with resistant or refractory chronic myeloid leukemia (CML) or
Philadelphia chrom... |
| | | 12/03/12 | ARIAD Announces Ponatinib Presentations at Annual American Society of Hematology Meeting| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 3, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the
presentations on ponatinib, its investigational BCR-ABL inhibitor, that
will take place at the 54th Annual Meeting of the American Society of
Hematology (ASH) being held in Atlanta, December 8 to 11, 2012. Updated
and new results on the PACE trial will be featured in five presentations
– two oral and three posters.
... |
| | | 11/28/12 | ARIAD Announces Publication of Ponatinib Phase 1 Clinical Trial Results in the New England Journal of Medicine|
Results demonstrate that ponatinib is highly active in heavily
pretreated patients with CML and Ph + ALL
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 28, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced publication of
results from the Phase 1 study of ponatinib, its investigational,
tyrosine kinase inhibitor in heavily pretreated patients with resistant
and refractory chronic myeloid leukemia (CML) and Philadelphia
c... |
| | | 11/13/12 | Foundation Medicine and ARIAD Announce Collaboration for Genomic Characterization of Patients in AP26113 Oncology Program| Collaboration will use genomic profiling to characterize patients treated with ARIAD’s investigational dual-inhibitor of ALK and EGFR
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. and ARIAD Pharmaceuticals, Inc. (ARIA) today announced a genomic profiling collaboration to study AP26113, ARIAD’s investigational dual-inhibitor of ALK and EGFR in patients with non-small cell lung cancer (NSCLC) and other cancers. Foundation Medicine will work with ARIAD to generate genomic profile i... |
| | | 11/08/12 | ARIAD to Present at the Lazard Capital Markets Healthcare Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 8, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will
present at the Lazard Capital Markets 9th Annual Healthcare
Conference being held in New York City. Harvey J. Berger, M.D., chairman
and chief executive officer, will provide an overview of the Company’s
progress on Wednesday, November 14, 2012 at 1:30 p.m. (ET).
The ARIAD presentation at the Lazard Capital Markets ... |
| | | 11/07/12 | ARIAD Reports Third Quarter 2012 Financial Results and Development Progress|
~ Ponatinib Regulatory Filings Under Review in the U.S. and E.U.
~Ready for Commercialization of Ponatinib in the U.S.
~ AP26113 Advancing Following First Clinical Presentation
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 7, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial
results for the third quarter and nine months ended September 30, 2012
and provided an update on corporate developments.
... |
| | | 10/31/12 | ARIAD to Webcast Conference Call on Third Quarter 2012 Financial Results| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 31, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will
host a live webcast of its quarterly conference call at 8:30 a.m. (ET)
on Wednesday, November 7, 2012. Harvey J. Berger, M.D., chairman and
chief executive officer, will host the call. Senior management will
discuss the Company’s financial results as of September 30, 2012 and
also address key corporate activities. The Comp... |
| | | 10/24/12 | ARIAD Announces U.S. Food and Drug Administration Acceptance of NDA Filing for Ponatinib| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 24, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the U.S.
Food and Drug Administration (FDA) has accepted for filing the New Drug
Application (NDA) for accelerated review of ARIAD’s investigational
BCR-ABL inhibitor, ponatinib,
in patients with resistant or intolerant chronic myeloid leukemia (CML)
or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+
ALL)... |
| | | 10/12/12 | ARIAD to Host Analyst & Investor Day in New York City| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 12, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its
Analyst & Investor Day for research analysts and institutional investors
will take place on Friday, October 19 at 8:00 a.m. (ET) in New York
City. Harvey
J. Berger, M.D., chairman and chief executive officer of ARIAD, will
host the event, which will include other key members of ARIAD executive
leadership. The meetin... |
| | | 09/29/12 | ARIAD Presents Initial Clinical Proof-of-Concept of AP26113 in Patients with Non-Small Cell Lung Cancer at ESMO 2012 Congress|
~ First evidence of clinical anti-tumor activity in patients
resistant to ALK or EGFR inhibitor therapy
~Investor conference call and webcast on Monday, October 1 at 8
a.m. ET
VIENNA & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 29, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the initial
clinical results on its investigational, tyrosine-kinase inhibitor, AP26113,
in patients with advanced non-small ... |
| | | 09/27/12 | ARIAD Completes Rolling Submission of New Drug Application for Ponatinib to the U.S. Food and Drug Administration| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 27, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced it has
completed the rolling submission of the New Drug Application (NDA) for
its investigational BCR-ABL inhibitor, ponatinib,
to the U.S. Food and Drug Administration (FDA). ARIAD provided the FDA
with remaining chemistry, manufacturing, and controls (CMC) data. ARIAD
is seeking U.S. marketing approval of ponatinib in patients with
... |
| | | 09/18/12 | MolecularMD and ARIAD Announce Voluntary Withdrawal Of MolecularMD’s Premarket Approval Application For BCR-ABL T315I Mutation Test|
~No Longer required as a Companion Diagnostic Test with Ponatinib
PORTLAND, Ore. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 18, 2012--
MolecularMD
Corp. and ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that
MolecularMD has voluntarily withdrawn its Premarketing Approval (PMA)
application to the U.S. Food and Drug Administration (FDA) for its
BCR-ABL T315I Mutation Test. The test detects the BCR-ABL T315I mutation
... |
| | | 09/17/12 | ARIAD Announces Initial Data on AP26113, Investigational Dual-Inhibitor of ALK and EGFR, to Be Presented at the ESMO 2012 Congress of the European Society for Medical Oncology|
~ Data from Dose-escalation Portion of Ongoing Phase 1/2 Clinical
Trial to be Presented on Saturday, September 29 at 11:15 a.m. (CEST)
~ Company to Host Investor Call and Webcast with Dr. Scott
Gettinger on Monday, October 1, 2012 at 8:00 a.m. (ET)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 17, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the
initial data from its Phase 1/2 trial of AP26113,
an inv... |
| | | 09/12/12 | ARIAD to Present at the UBS Global Life Sciences Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 12, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will
present at the UBS Global Life Sciences conference being held in New
York City. Harvey J. Berger, M.D., chairman and chief executive officer,
will provide an overview of the Company’s business on Wednesday,
September 19, 2012 at 9:00 a.m. (ET).
The ARIAD presentation at the UBS Global Life Sciences Conference will
... |
| | | 09/04/12 | ARIAD to Present at Upcoming Investor Conferences| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 4, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that Harvey J.
Berger, M.D., chairman and chief executive officer, will provide an
overview of the Company’s business at two upcoming investor conferences
being held next week:
The Rodman & Renshaw 14th Annual Healthcare Conference
in New York City. Dr. Berger’s presentation is on Monday, September 10
at... |
| | | 08/30/12 | ARIAD Announces Submission of Marketing Authorization Application for Ponatinib to the European Medicines Agency| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 30, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the submission
of a Marketing Authorization Application (MAA) for its investigational
BCR-ABL inhibitor, ponatinib, to the European Medicines Agency (EMA).
ARIAD is seeking marketing approval in the European Union of ponatinib
in adult patients with resistant or intolerant chronic myeloid leukemia
(CML) and Philadelphia-chromosome posi... |
| | | 08/29/12 | ARIAD to Present at the Stifel Nicolaus Healthcare Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 29, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will
present at the Stifel Nicolaus Healthcare conference in Boston. Timothy
P. Clackson, Ph.D., president of research and development and chief
scientific officer, will provide an overview of the Company’s business
on Wednesday, September 5, 2012 at 4:25 p.m. (ET).
The ARIAD presentation at the Stifel Nicolaus Healthca... |
| | | 08/20/12 | ARIAD Begins Phase 1/2 Trial of Ponatinib in Japan|
Trial to evaluate ponatinib in Japanese patients with CML who are
resistant or intolerant to prior therapy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 20, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the initiation
of a multi-center Phase 1/2 clinical trial in Japan of ponatinib,
the Company’s investigational BCR-ABL inhibitor. The trial is being
conducted in Japanese patients with chronic myeloid leukemia (CML) who
... |
| | | 08/02/12 | ARIAD Reports Second Quarter 2012 Financial Results and Development Progress|
~ Ponatinib NDA Under Review at FDA
~ Phase 3 EPIC Trial of Ponatinib Now Enrolling Patients
~ Ponatinib Granted Accelerated Assessment in Europe by CHMP
~ Early Phase 1/2 Trial Data on AP26113 to be Presented at ESMO
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 2, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial
results for the second quarter and six months ended June 30, 2012 and
pr... |
| | | 07/30/12 | Ariad Announces Submission of New Drug Application for Ponatinib to the U.S. Food and Drug Administration| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 30, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the submission
of a New Drug Application (NDA) for its investigational BCR-ABL
inhibitor, ponatinib, to the U.S. Food and Drug Administration (FDA).
ARIAD is seeking U.S. marketing approval of ponatinib in patients with
resistant or intolerant chronic myeloid leukemia (CML) and
Philadelphia-chromosome positive acute lymphoblastic leuke... |
| | | 07/27/12 | ARIAD Announces Initiation of Randomized Phase 3 Trial of Ponatinib in Newly Diagnosed Patients with Chronic Myeloid Leukemia| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 27, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the initiation
of the randomized Phase 3 trial of ponatinib,
its investigational pan-BCR-ABL inhibitor, in adult patients with newly
diagnosed chronic myeloid leukemia (CML). The EPIC (Evaluation
of Ponatinib versus Imatinib in Chronic Myeloid
Leukemia) trial is designed to provide definitive clinical data to
support regulatory ... |
| | | 07/17/12 | ARIAD to Webcast Conference Call on Second Quarter 2012 Financial Results| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 17, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will
host a live webcast of its quarterly conference call at 8:30 a.m. (ET)
on Thursday, August 2, 2012. Harvey J. Berger, M.D., chairman and chief
executive officer, will host the call. Senior management will discuss
the Company’s financial results as of June 30, 2012, key corporate
objectives and additional corporate activiti... |
| | | 07/05/12 | ARIAD to Present at the JMP Securities 2012 Healthcare Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 5, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will
present at the seventh annual JMP Securities Healthcare Conference being
held at the Peninsula Hotel in New York City. Timothy P. Clackson,
Ph.D., president of research and development and chief scientific
officer, will provide an overview of the Company’s business on Friday,
July 13, 2012 at 10:30 a.m. (ET).
... |
| | | 06/18/12 | ARIAD Announces Updated Data From Pivotal PACE Trial of Ponatinib, its Investigational Pan-BCR-ABL Inhibitor| AMSTERDAM and CAMBRIDGE, Massachusetts, June 18, 2012 /PRNewswire via COMTEX/ --~ Robust anti-leukemic activity in CML patients who have become resistant or intolerant to available tyrosine kinase inhibitors
~ 54% major cytogenetic response and 30% major molecular response reported in heavily pre-treated chronic-phase CML patients
~ Data supports ARIAD filing for EMA approval of ponatinib in Europe
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical data from the... |
| | | 06/14/12 | ARIAD Announces Webcast of Its Annual Shareholders Meeting| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 14, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its Annual
Meeting of Stockholders will be webcast live on June 21, 2012 and can be
accessed by visiting the investor relations section of the Company's
website at http://www.ariad.com/investor.
The annual meeting will take place at 10:00 a.m. (EDT) at the Company's
offices in Cambridge, Massachusetts and will include an o... |
| | | 06/04/12 | ARIAD Announces Updated Data from Pivotal PACE Trial of Ponatinib, Its Investigational pan-BCR-ABL Inhibitor|
~ Robust anti-leukemic activity in CML patients who have become
resistant or intolerant to available tyrosine kinase inhibitors
~ 54 percent major cytogenetic response and 30 percent major
molecular response reported in heavily pretreated chronic-phase CML
patients
~ Investor meeting and webcast to be held today at 12:00 p.m. (CT)
CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 4, 2012--
ARIAD
Pharmaceutica... |
| | | 05/30/12 | ARIAD to Present at Upcoming Investor Conferences| CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 30, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that Harvey J.
Berger, M.D., chairman and chief executive officer, and Timothy P.
Clackson, Ph.D., president of research and development and chief
scientific officer, will provide an overview of the Company’s business
at two upcoming investor conferences:
The Goldman Sachs 33rd Annual Global Healthcare Conference in R... |
| | | 05/16/12 | Ariad Announces Updated Findings from Pivotal Pace Trial of Ponatinib to Be Presented at Annual Meeting of American Society of Clinical Oncology|
~ Data to Form the Basis of ARIAD’s Regulatory Filings for Marketing
Approval of Ponatinib
~ Company to Host Investor Meeting and Webcast with Dr. Jorge Cortes
on Monday, June 4 at 12pm (CT)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 16, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that updated
clinical data from the pivotal PACE trial of its investigational,
pan-BCR-ABL inhibitor, ponatinib,
wil... |
| | | 05/10/12 | ARIAD to Present at Bank of America Merrill Lynch 2012 Health Care Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 10, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will
webcast its presentation at the Bank of America Merrill Lynch 2012
Health Care Conference in Las Vegas. Harvey J. Berger, M.D., chairman
and chief executive officer, will provide an overview of the Company’s
business on Wednesday, May 16, 2012 at 9:20 a.m. (PT).
The ARIAD presentation at the Bank of America Merrill... |
| | | 05/09/12 | ARIAD Reports First Quarter 2012 Financial Results and Development Progress|
Ponatinib On Track for PACE Trial Data Presentation at ASCO and
Regulatory Filings in 3Q 2012 for Marketing Approval
AP26113 Moving Through Dosing Cohorts in Phase 1/2 Trial
Conference Call Scheduled Today at 8:30 a.m. ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 9, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial
results for the first quarter ended March 31, 2012 and provided an
update on... |
| | | 04/30/12 | ARIAD To Present at the Deutsche Bank 37th Annual Health Care
Conference| CAMBRIDGE, Mass., Apr 30, 2012 (BUSINESS WIRE) --ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will
webcast its presentation at the Deutsche Bank 37th Annual Health Care
Conference in Boston. Harvey J. Berger, M.D., chairman and chief
executive officer, will provide an overview of the Company's business on
Monday, May 7, 2012 at 4:10 p.m. (ET).
The ARIAD presentation at the Deutsche Bank 37th Annual Health Care
Conference wi... |
| | | 04/25/12 | ARIAD to Webcast Conference Call on First Quarter 2012 Financial
Results| CAMBRIDGE, Mass., Apr 25, 2012 (BUSINESS WIRE) --ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will
host a live webcast of its quarterly conference call at 8:30 a.m. (ET)
on Wednesday, May 9, 2012. Harvey J. Berger, M.D., chairman and chief
executive officer, will host the call. ARIAD senior management will
discuss the Company's financial results as of March, 31, 2012, as well
as key corporate objectives and additional corporate activi... |
| | | 04/02/12 | ARIAD Presents New Preclinical Data on Ponatinib and AP26113|
Both Tyrosine Kinase Inhibitors Overcome Drug Resistance Due to
“Gatekeeper” Mutations Of Multiple Oncogenic Targets
CAMBRIDGE, Mass. & CHICAGO--(BUSINESS WIRE)--Apr. 2, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the
presentation of new preclinical data on its investigational pan-BCR-ABL
inhibitor, ponatinib,
and its investigational dual EGFR-ALK inhibitor, AP26113, at the
American Association for Canc... |
| | | 03/26/12 | ARIAD Announces Presentations of Preclinical Data at American Association for Cancer Research Annual Meeting| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 26, 2012-- ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced its
schedule of preclinical data presentations to be made at the
American Association for Cancer Research (AACR) Annual
Meeting 2012, taking place Saturday, March 31 through
Wednesday, April 4, 2012, in Chicago.
Listed below are the details of presentations at AACR that
describe ARIAD's product candidates or research programs. There will
be three pres... |
| | | 03/20/12 | Merck and ARIAD Pharmaceuticals Provide Update on FDA Advisory Committee Vote on Investigational Medicine Ridaforolimus for the Treatment of Metastatic Soft-Tissue or Bone Sarcomas| WHITEHOUSE STATION, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 20, 2012-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and ARIAD Pharmaceuticals, Inc., (NASDAQ:ARIA), announced today that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 13 to 1 against the use of the investigational agent ridaforolimus as maintenance therapy for patients with metastatic soft-tissue sarcoma or bone sarcoma whose disease has not progress... |
| | | 03/06/12 | ARIAD to Present at Barclays Capital Global Healthcare Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 6, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will
webcast its presentation at the Barclays Capital Global Healthcare
Conference in Miami. Harvey J. Berger, M.D., chairman and chief
executive officer, will provide an overview of the Company’s business on
Tuesday, March 13, 2012 at 10:45 a.m. (ET).
The ARIAD presentation at the Barclays Capital Global Healthcare
... |
| | | 02/28/12 | ARIAD Reports 2011 Financial Results and Outlines Key Development and Commercialization Plans for 2012|
Positive preliminary clinical results and strong financial
position advance Company towards global commercialization
Conference Call Scheduled Today at 8:30 a.m. ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 28, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial
results for the fourth quarter and full year ended December 31, 2011 and
provided an update on corporate developments.
“The past yea... |
| | | 02/27/12 | ARIAD to Present at the Cowen and Company 32nd Annual Health Care Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 27, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will
webcast its presentation at the Cowen and Company 32nd Annual
Health Care Conference in Boston. Harvey J. Berger, M.D., chairman and
chief executive officer, will provide an overview of the Company’s
business on Tuesday, March 6, 2012 at 9:20 a.m. (ET).
The ARIAD presentation at the Cowen and Company 32nd Annual
... |
| | | 02/22/12 | ARIAD to Present at Citi 2012 Global Health Care Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 22, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will
webcast its presentation at the Citi 2012 Global Health Care Conference
in New York City. Harvey J. Berger, M.D., chairman and chief executive
officer, will provide an overview of the Company’s business on
Wednesday, February 29, 2012 at 8:30 a.m. (ET).
The ARIAD presentation at the Citi 2012 Global Health Care Con... |
| | | 02/15/12 | ARIAD Announces Issuance of Key U.S. Patent on Ponatinib| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 15, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the United
States Patent and Trademark Office has granted U.S. Patent No. 8,114,874
entitled, “Substituted Acetylenic Imidazo[1,2-B] Pyridazine Compounds as
Kinase Inhibitors,” which provides composition-of-matter patent
protection through at least December 22, 2026 for ARIAD’s
investigational pan-BCR-ABL inhibitor, ponatinib. Thi... |
| | | 02/14/12 | ARIAD to Webcast Conference Call on Fourth Quarter and Year-End 2011 Financial Results| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 14, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will
host a live webcast of its quarterly conference call at 8:30 a.m. (ET)
on Tuesday, February 28, 2012. Harvey J. Berger, M.D., chairman and
chief executive officer, will host the call. Senior management will
discuss the Company’s financial results as of December 31, 2011, key
corporate objectives and additional corporate ac... |
| | | 02/02/12 | ARIAD to Present at Upcoming Investor Conferences| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 2, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that Harvey J.
Berger, M.D., chairman and chief executive officer, will provide an
overview of the Company’s business at two upcoming investor conferences:
The 14th Annual BIO CEO & Investor Conference in New York
City. Dr. Berger’s presentation is on Monday, February 13 at 9:00 a.m.
(ET)
... |
| | | 01/04/12 | ARIAD to Present at the 30th Annual J.P. Morgan Healthcare Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 4, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will
webcast its presentation at the 30th Annual J.P. Morgan
Healthcare Conference in San Francisco. Harvey J. Berger, M.D., chairman
and chief executive officer, will provide an overview of the Company’s
business on Tuesday, January 10, 2012 at 10:00 a.m. (PT).
The ARIAD presentation at the J.P. Morgan Healthcare Confer... |
| | | 01/03/12 | ARIAD to Trade on the NASDAQ Global Select Market| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 3, 2012--
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the
Company has been upgraded to trade on the NASDAQ Global Select Market,
the top listing tier for NASDAQ companies with the highest initial
listing standards of any exchange in the world based on financial and
liquidity requirements. Shares of ARIAD common stock will begin trading
on the NASDAQ Global Select Market effective today.
... |
| |
|
